 | |
| Company type | Public |
|---|---|
| Nasdaq: BCRX Russell 2000 Component | |
| Industry | Healthcare |
| Founded | 1986 |
| Headquarters | Durham, North Carolina, US |
Key people | Jon P. Stonehouse (president and CEO) |
| Products | RABIVAP |
| Revenue |  $49 million (2019)[1] |
Number of employees | 110 |
| Website | www.biocryst.com |
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China.